New drug combo aims to outsmart Hard-to-Treat lymphoma
NCT ID NCT07697339
First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time
Summary
This clinical trial is testing whether adding an experimental drug called HDM2005 to a standard treatment (rituximab and lenalidomide) can help people with mantle cell lymphoma whose cancer has returned or not responded to previous therapies. The study involves about 40 adults and has two parts: first, to find the safest dose of HDM2005, and then to compare the combination against other standard treatments. The main goals are to see if the new combination shrinks tumors and delays cancer growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HDM2005 (a targeted therapy) combined with rituximab and lenalidomide
- What this could lead to
- If successful, this combination could offer a new treatment option for patients with mantle cell lymphoma that has returned or stopped responding to prior therapies.
- What could go wrong
- This is an early-phase study with a small number of participants, so the benefits are uncertain. Side effects from the drug combination may occur, and the treatment may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a cancer drug reboot the immune system after a stem cell transplant?
- Can a targeted drug boost standard chemo for a rare blood cancer?
- Smartwatches track hidden heart risk in blood cancer patients
- Triple-Drug attack aims to outsmart mantle cell lymphoma
- Double-Pronged immune cells take aim at stubborn blood cancers
- Engineered immune cells get a boost: new combo therapy targets Hard-to-Treat blood cancers